ORM-12741
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- ORM-12741
- DrugBank Accession Number
- DB12057
- Background
ORM-12741 has been used in trials studying the basic science and treatment of Alzheimer's Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for ORM-12741 (DB12057)
- Weight
- Average: 285.387
Monoisotopic: 285.172878985 - Chemical Formula
- C18H23NO2
- Synonyms
- Not Available
- External IDs
- ORM-10921
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlfuzosin ORM-12741 may increase the hypotensive activities of Alfuzosin. Amphetamine The therapeutic efficacy of ORM-12741 can be decreased when used in combination with Amphetamine. Arbutamine The therapeutic efficacy of Arbutamine can be decreased when used in combination with ORM-12741. Arformoterol The therapeutic efficacy of Arformoterol can be decreased when used in combination with ORM-12741. Benzphetamine The therapeutic efficacy of ORM-12741 can be decreased when used in combination with Benzphetamine. Bethanidine The therapeutic efficacy of Bethanidine can be decreased when used in combination with ORM-12741. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with ORM-12741. Celiprolol The therapeutic efficacy of Celiprolol can be decreased when used in combination with ORM-12741. Clenbuterol The therapeutic efficacy of Clenbuterol can be decreased when used in combination with ORM-12741. Clonidine The therapeutic efficacy of Clonidine can be decreased when used in combination with ORM-12741. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzofurans
- Sub Class
- Not Available
- Direct Parent
- Benzofurans
- Alternative Parents
- Aralkylamines / Piperidines / Benzenoids / Heteroaromatic compounds / Furans / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Hydrocarbon derivatives
- Substituents
- Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzofuran / Dialkyl ether / Ether / Furan / Heteroaromatic compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- D26C95A960
- CAS number
- 610782-82-6
- InChI Key
- OCUKPFWNSAAHRP-QZTJIDSGSA-N
- InChI
- InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1
- IUPAC Name
- (2S,3S)-3-(methoxymethyl)-3-methyl-17-oxa-7-azatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),11,13,15-tetraene
- SMILES
- COC[C@@]1(C)CCCN2CCC3=C(OC4=CC=CC=C34)[C@H]12
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Alzheimer's Disease (AD) 2 1 Completed Not Available Healthy Volunteers 1 1 Completed Basic Science Healthy Volunteers 2 1 Completed Treatment Healthy Male Volunteers 1 1 Completed Treatment Healthy Volunteers 5 0 Completed Basic Science Healthy Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0307 mg/mL ALOGPS logP 3.66 ALOGPS logP 3.05 ChemAxon logS -4 ALOGPS pKa (Strongest Basic) 7.41 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 25.61 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 83.84 m3·mol-1 ChemAxon Polarizability 33.3 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 21:16 / Updated on June 12, 2020 16:53